Fulgent Genetics, Inc. (FLGT)

20.89 +0.34 (+1.65%) At close: 04:00PM EDT

Fulgent Genetics, Inc.

4399 Santa Anita Avenue
El Monte, CA 91731
United States
626 350 0537
https://www.fulgentgenetics.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 1,184

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Ming Hsieh	Chairman & CEO	2.31M	N/A	1956
Mr. Jian Xie	COO & President	868.74k	N/A	1966
Mr. Paul Kim	Chief Financial Officer	879.61k	N/A	1967
Dr. Hanlin Gao D.A.B.M.G., FACMG, M.D., Ph.D.	Chief Scientific Officer & Laboratory Director	720.7k	N/A	1967
Ms. Natalie Prescott	General Counsel & Chief Privacy Officer	N/A	N/A	N/A
Ms. Doreen Ng	VP of Operations & Compliance and GM of Houston Office	N/A	N/A	N/A
Mr. Jakub Sram	Vice President of Business Development & Sales	N/A	N/A	N/A
Ms. Ellen Tsui	Vice President of Human Resources	N/A	N/A	N/A
Mr. Brandon Perthuis	Chief Commercial Officer	N/A	N/A	N/A
Dr. Lawrence M. Weiss M.D.	Chief Medical Officer	N/A	N/A	1957

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Corporate governance

Fulgent Genetics, Inc.’s ISS governance QualityScore as of 1 October 2024 is 6. The pillar scores are Audit: 5; Board: 8; Shareholder rights: 4; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.